Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO), has collaborated with George Medicines, a late-stage biopharma company, to develop WIDAPLIK, a new drug for the treatment of hypertension in adult patients. The US Food and Drug Administration (FDA) approved WIDAPLIK on June 6, 2025. WIDAPLIK is a single pill combination of three medicines: telmisartan, amlodipine, and indapamide, developed in three doses. It is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals.
The collaboration between George Medicines and Piramal Pharma Solutions began in December 2018, when the formulation was developed at Piramal’s Pharmaceutical Development site in Ahmedabad. The project was later transferred to Piramal’s drug product facility in Pithampur for validation and manufacturing. Piramal’s technical expertise and experience in advancing innovations played a significant role in achieving FDA approval for WIDAPLIK.
WIDAPLIK’s multi-mechanism approach and available doses are designed to deliver the blood pressure-lowering benefits of a triple combination therapy early in the treatment pathway, with the established safety profile of its three component antihypertensive medications. The drug is available in three strengths, including two doses that are lower than those currently available in single pill combinations.
The approval of WIDAPLIK marks a significant milestone in the treatment of hypertension, offering a new option for patients who require multiple medications to achieve blood pressure goals. Piramal Pharma Solutions’ robust CDMO capabilities and George Medicines’ commitment to developing innovative treatments have made this breakthrough possible. The collaboration demonstrates the importance of partnerships in advancing medical innovation and improving patient outcomes. With WIDAPLIK now approved, patients with hypertension can expect a more effective and convenient treatment option.